Trial | NCT04303520  Report issue

Title

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL
A Phase I Clinical Trial of T-Cells Targeting CD19 and CD22 for Subjects With CD19-positive Acute Lymphoblastic Leukemia

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    20
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/CD22 bispecific chimeric antigen receptors (CARs) T cell therapy for CD19-positive Acute Lymphoblastic Leukemia.
Primary Objectives

1. To determine the feasibility ad safety of anti-CD19/ CD22 CAR-T cells in treating patients with CD19-positive Acute Lymphoblastic Leukemia.

Secondary Objectives

To determine in vivo expression, dynamics and persistency of anti-CD19/CD22 CAR-T cells.
To determine in vivo expression of CD19-positive B cells.
To access the complete remission rate (ORR) in patients with ALL with 3 months after CD19/CD22 CAR-T cells infusion.
To investigate the favorable CD19/CD22 CAR-T cells dose and dosage regimen for the Phase II Clinical Trial.
Study Started
May 03
2018
Primary Completion
Sep 30
2020
Anticipated
Study Completion
Feb 28
2021
Anticipated
Last Update
Mar 11
2020

Biological anti-CD19/CD22 CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs

Drug Fludarabine

30mg/m2/d

Drug Cyclophosphamide

500mg/m2/d

anti-CD19/CD22 CAR-T cells Experimental

Administration with anti-CD19/CD22 CAR-T cells in the CD19-positive ALL patients

Criteria 

Inclusion Criteria:

13 Years to 70 Years, Male and female;
Expected survival > 12 weeks;
Clinical performance status of ECOG score 0-2;

Histologically confirmed as CD19-positive lymphoma and who meet one of the following conditions:

Patients received at least 2 prior combination chemotherapy regimens (not including single agent monoclonal antibody therapy) and fail to achieve CR; or have disease recurrence; or not eligible for allogeneic stem cell transplantation; or disease responding or stable after most recent therapy but refused further treatment;
Disease recurrence after stem cell transplantation.
Accessible to intravenous injection, and no white blood cell collection contraindications

Patients who meet the following conditions:

Creatinine < 2.5 mmol/l;
Cardiac ejection fraction>50%, no pericardial effusion and no pleural effusion (ECHO examination);
Baseline oxygen saturation>92%;
Total bilirubin≤1.5xULN;
ALT/AST≤2.5x normal.
Able to understand and sign the Informed Consent Document.

Exclusion Criteria:

Accompanied by other malignant tumor
Active hepatitis B, hepatitis C, syphilis, HIV infection
Suffering severe cardiovascular or respiratory disease
Any other diseases could affect the outcome of this trial
Any affairs could affect the safety of the subjects or outcome of this trial
Pregnant or lactating women, or patients who plan to be pregnancy during or after treatment
Occurrence of infection uncontrolled or requiring systemic treatment 14 days prior to assignment
Patients who are accounted by researchers to be not appropriate for this test
Received CAR-T treatment or other gene therapies before assignment
Patients with symptoms of central nervous system
Subject suffering disease affects the understanding of informed consent or comply with study protocol.
No Results Posted